Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.

Akira Mitsuhashi, Takako Kiyokawa, Yasunori Sato, Makio Shozu

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin-induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer. A dose of metaformin was administered (1500-2250 mg/day) to 31 patients with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2-sided. P values of < .05 were considered statistically significant. Preoperative metformin treatment decreased DNA synthesis in sera and significantly reduced the Ki-67 (mean proportional decrease, 44.2%; 95% confidence interval [95% CI], 35.4-53.0 [P < .001]) and topoisomerase IIα (mean proportional decrease, 36.4%; 95% CI, 26.7-46.0 [P < .001]) labeling indices. Levels of phospho-ribosomal protein S6 and phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) were found to be significantly decreased and phospho-adenosine monophosphate-activated protein kinase and p27 levels were significantly increased. Preoperative metformin use caused significant decreases in circulating factors, including insulin, glucose, insulin-like growth factor 1, and leptin. DNA synthesis-stimulating activity in patient sera was significantly decreased during metformin administration. An antidiabetic dose of metformin inhibited endometrial cancer cell growth in vivo, an effect likely due to its effect on humoral factor(s). This translational study provides considerable rationale to initiate large clinical trials.

Original languageEnglish
Pages (from-to)2986-2995
Number of pages10
JournalCancer
Volume120
Issue number19
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Metformin
Endometrial Neoplasms
Growth
Hypoglycemic Agents
DNA
Serum
Ribosomal Protein S6
Cell Proliferation
Confidence Intervals
Neoplasms
Type II DNA Topoisomerase
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Somatomedins
Adenosine Monophosphate
Leptin
Thymidine
Protein Kinases
Insulin Resistance
Western Blotting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of metformin on endometrial cancer cell growth in vivo : a preoperative prospective trial. / Mitsuhashi, Akira; Kiyokawa, Takako; Sato, Yasunori; Shozu, Makio.

In: Cancer, Vol. 120, No. 19, 01.01.2014, p. 2986-2995.

Research output: Contribution to journalArticle

Mitsuhashi, Akira ; Kiyokawa, Takako ; Sato, Yasunori ; Shozu, Makio. / Effects of metformin on endometrial cancer cell growth in vivo : a preoperative prospective trial. In: Cancer. 2014 ; Vol. 120, No. 19. pp. 2986-2995.
@article{93e517109cb24518a1e4c4d26d7da9df,
title = "Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.",
abstract = "Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin-induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer. A dose of metaformin was administered (1500-2250 mg/day) to 31 patients with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2-sided. P values of < .05 were considered statistically significant. Preoperative metformin treatment decreased DNA synthesis in sera and significantly reduced the Ki-67 (mean proportional decrease, 44.2{\%}; 95{\%} confidence interval [95{\%} CI], 35.4-53.0 [P < .001]) and topoisomerase IIα (mean proportional decrease, 36.4{\%}; 95{\%} CI, 26.7-46.0 [P < .001]) labeling indices. Levels of phospho-ribosomal protein S6 and phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) were found to be significantly decreased and phospho-adenosine monophosphate-activated protein kinase and p27 levels were significantly increased. Preoperative metformin use caused significant decreases in circulating factors, including insulin, glucose, insulin-like growth factor 1, and leptin. DNA synthesis-stimulating activity in patient sera was significantly decreased during metformin administration. An antidiabetic dose of metformin inhibited endometrial cancer cell growth in vivo, an effect likely due to its effect on humoral factor(s). This translational study provides considerable rationale to initiate large clinical trials.",
author = "Akira Mitsuhashi and Takako Kiyokawa and Yasunori Sato and Makio Shozu",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/cncr.28853",
language = "English",
volume = "120",
pages = "2986--2995",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Effects of metformin on endometrial cancer cell growth in vivo

T2 - a preoperative prospective trial.

AU - Mitsuhashi, Akira

AU - Kiyokawa, Takako

AU - Sato, Yasunori

AU - Shozu, Makio

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin-induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer. A dose of metaformin was administered (1500-2250 mg/day) to 31 patients with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2-sided. P values of < .05 were considered statistically significant. Preoperative metformin treatment decreased DNA synthesis in sera and significantly reduced the Ki-67 (mean proportional decrease, 44.2%; 95% confidence interval [95% CI], 35.4-53.0 [P < .001]) and topoisomerase IIα (mean proportional decrease, 36.4%; 95% CI, 26.7-46.0 [P < .001]) labeling indices. Levels of phospho-ribosomal protein S6 and phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) were found to be significantly decreased and phospho-adenosine monophosphate-activated protein kinase and p27 levels were significantly increased. Preoperative metformin use caused significant decreases in circulating factors, including insulin, glucose, insulin-like growth factor 1, and leptin. DNA synthesis-stimulating activity in patient sera was significantly decreased during metformin administration. An antidiabetic dose of metformin inhibited endometrial cancer cell growth in vivo, an effect likely due to its effect on humoral factor(s). This translational study provides considerable rationale to initiate large clinical trials.

AB - Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin-induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer. A dose of metaformin was administered (1500-2250 mg/day) to 31 patients with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2-sided. P values of < .05 were considered statistically significant. Preoperative metformin treatment decreased DNA synthesis in sera and significantly reduced the Ki-67 (mean proportional decrease, 44.2%; 95% confidence interval [95% CI], 35.4-53.0 [P < .001]) and topoisomerase IIα (mean proportional decrease, 36.4%; 95% CI, 26.7-46.0 [P < .001]) labeling indices. Levels of phospho-ribosomal protein S6 and phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) were found to be significantly decreased and phospho-adenosine monophosphate-activated protein kinase and p27 levels were significantly increased. Preoperative metformin use caused significant decreases in circulating factors, including insulin, glucose, insulin-like growth factor 1, and leptin. DNA synthesis-stimulating activity in patient sera was significantly decreased during metformin administration. An antidiabetic dose of metformin inhibited endometrial cancer cell growth in vivo, an effect likely due to its effect on humoral factor(s). This translational study provides considerable rationale to initiate large clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84908498848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908498848&partnerID=8YFLogxK

U2 - 10.1002/cncr.28853

DO - 10.1002/cncr.28853

M3 - Article

C2 - 24917306

AN - SCOPUS:84908498848

VL - 120

SP - 2986

EP - 2995

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -